Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
Adrian Sacher,Patricia LoRusso,Manish R Patel,Wilson H Miller Jr,Elena Garralda,Martin D Forster,Armando Santoro,Alejandro Falcon,Tae Won Kim,Luis Paz-Ares,Samantha Bowyer,Maria de Miguel,Sae-Won Han,Matthew G Krebs,Jong-Seok Lee,Michael L Cheng,Kathryn Arbour,Erminia Massarelli,Yoonha Choi,Zhen Shi,Sandhya Mandlekar,Mark T Lin,Stephanie Royer-Joo,Julie Chang,Neekesh V Dharia,Jennifer L Schutzman,Jayesh Desai,GO42144 Investigator and Study Group,Rasha Cosman,Ben Markman,Pierre Freres,Marc Lambrechts,Hans Prenen,Carlos Barrios,Joao Daniel Cardoso Guedes,Sergio De Azevedo,Rita De Cassia Costamilan,Carolina Gomes Jacobina Silva,Tabatha Nakakogue Dallagnol,Scott Laurie,Wilson Miller,István Láng,Istvan Takacs,Ravit Geva,Ruth Perets,Einat Shacham-Shmueli,Chiara Cremolini,Gianluca Del Conte,Angelo Del Monte,Salvatore Siena,Mansoor Saleh,Myung-Ju Ahn,Hans Gelderblom,Eelke Gort,Loes Latten-Jansen,Marloes Van Dongen,Sanjeev Deva,Rajiv Kumar,Øystein Fløtten,Tormod Guren,Rafal Dziadziuszko,Jacek Mackiewicz,Rafal Stec,Rustem Safin,Andres Cervantes Ruizperez,Maria De Miguel Luken,Elena Garralda Cabanas,Laura Medina,Victor Moreno,Luiz Paz-Ares Rodriguez,Christian Britschgi,Eugenio Fernandez,Simon Häfliger,Sacha Rothschild,Martin Forster,Robert Jones,Matthew Krebs,Raid Aljumaily,Lyudmila Bazhenova,Timothy Burns,Michael Cheng,Thomas Karasic,Pamela Munster,Sai-Hong Ou,Manish Patel,Junko Aimi,Xuefeng Hou,Tomi Jun,Huy Ngo,Nina Qi,Julia Suchomel,Kenneth K Yau
DOI: https://doi.org/10.1056/NEJMoa2303810
2023-08-24
Abstract:Background: Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. Methods: In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients who had advanced or metastatic solid tumors that harbor a KRAS G12C mutation. The primary objective was an assessment of safety; pharmacokinetics, investigator-evaluated antitumor activity, and biomarkers of response and resistance were also assessed. Results: A total of 137 patients (60 with non-small-cell lung cancer [NSCLC], 55 with colorectal cancer, and 22 with other solid tumors) received divarasib. No dose-limiting toxic effects or treatment-related deaths were reported. Treatment-related adverse events occurred in 127 patients (93%); grade 3 events occurred in 15 patients (11%) and a grade 4 event in 1 patient (1%). Treatment-related adverse events resulted in a dose reduction in 19 patients (14%) and discontinuation of treatment in 4 patients (3%). Among patients with NSCLC, a confirmed response was observed in 53.4% of patients (95% confidence interval [CI], 39.9 to 66.7), and the median progression-free survival was 13.1 months (95% CI, 8.8 to could not be estimated). Among patients with colorectal cancer, a confirmed response was observed in 29.1% of patients (95% CI, 17.6 to 42.9), and the median progression-free survival was 5.6 months (95% CI, 4.1 to 8.2). Responses were also observed in patients with other solid tumors. Serial assessment of circulating tumor DNA showed declines in KRAS G12C variant allele frequency associated with response and identified genomic alterations that may confer resistance to divarasib. Conclusions: Treatment with divarasib resulted in durable clinical responses across KRAS G12C-positive tumors, with mostly low-grade adverse events. (Funded by Genentech; ClinicalTrials.gov number, NCT04449874.).